Avalon GloboCare Corp. (ALBT)
Company Description
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China.
The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.
It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited.
Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education.
The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Country | United States |
Founded | 2014 |
Industry | Real Estate Services |
Sector | Real Estate |
Employees | 5 |
CEO | Dr. David K. Jin M.D., Ph.D. |
Contact Details
Address: 4400 Route 9, Suite 3100 Freehold, New Jersey 07728 United States | |
Phone | 732-780-4400 |
Website | avalon-globocare.com |
Stock Details
Ticker Symbol | ALBT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001630212 |
ISIN Number | US05344R2031 |
Employer ID | 47-1685128 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. David K. Jin M.D., Ph.D. | Chief Executive Officer, President and Director |
Luisa Ingargiola | Chief Financial Officer |
Meng Li | Chief Operating Officer, Chief Marketing Officer and Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 8-K | Current Report |
Jan 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 22, 2023 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Oct 20, 2023 | D | Notice of Exempt Offering of Securities |
Oct 13, 2023 | 8-K | Current Report |
Oct 13, 2023 | 8-K | Current Report |
Sep 8, 2023 | ARS | Filing |
Sep 8, 2023 | DEF 14A | Other definitive proxy statements |